Linked Life Data

16580257

Source:http://linkedlifedata.com/resource/pubmed/id/16580257

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-5-15
pubmed:abstractText
Carbon monoxide (CO) offers potential therapeutic avenues in the treatment of lung disorders. CO arises endogenously from heme degradation, catalyzed by the heme oxygenase enzymes. In cell culture, CO exerts potent anti-inflammatory, anti-apoptotic and anti-proliferative effects by modulating intracellular signaling pathways. In vivo, CO confers tissue protection in animal models of lung disease, including those with oxidative and inflammatory lung injury and ischemia/reperfusion injury. Furthermore, low-dose CO ameliorates vascular injury and reduces the rejection rate of lung and vascular grafts. Recent advances include the observation that CO protects the lung in models of bleomycin-induced lung fibrosis and ventilator-induced lung injury. Despite the success of CO therapy in animal models, the utility of CO as therapy in humans remains uncertain.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1471-4892
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
257-62
pubmed:dateRevised
2007-12-3
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Therapeutic applications of carbon monoxide in lung disease.
pubmed:affiliation
Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, The University of Pittsburgh School of Medicine, MUH 628 NW, 3459 Fifth Ave, Pittsburgh PA 15213, USA. Ryters@upmc.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural